Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Uveal Neoplasms, bronchial neoplasm, bronchogenic carcinoma, digestive system disorder, digestive system neoplasm, eye disorder, gastric neoplasm, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, ocular cancer, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, stomach disorder, uveal disorder, uveal melanoma	Active, not recruiting	Phase 1 / Phase 2	2026-07-13		NCT04130516

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Linnaeus Therapeutics, Inc.	2
Merck Sharp & Dohme LLC	650

10 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Cedars-Sinai Medical Center	Los Angeles	United States	392
Columbia University Herbert Irving Comprehensive Cancer Center	New York	United States	7
Massachusetts General Hospital	Boston	United States	1015
MD Anderson Cancer Center	Houston	United States	589
Memorial Sloan Kettering Cancer Center	New York	United States	1000
The START Center for Cancer Care	San Antonio	United States	2
Thomas Jefferson University, Sidney Kimmel Cancer Center	Philadelphia	United States	14
University of New Mexico Comprehensive Cancer Center	Albuquerque	United States	4
University of Pennsylvania	Philadelphia	United States	8
Yale Cancer Center	New Haven	United States	15